ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

What is the breakdown of revenue by product line or therapeutic area, and which segments contributed most to the growth? What is the cash position and net burn rate after the 2Q 2025 results, and how does that affect runway for upcoming programs? Are there any upcoming regulatory milestones (e.g., FDA filings, approvals, or clinical trial readouts) that could materially affect the stock in the near term? What guidance did management provide for revenue, earnings, and cash flow for the remainder of 2025, and how does it compare to prior guidance and consensus forecasts? How does the current valuation (EV/Revenue, P/E, etc.) compare to historical levels and to peer companies? How did operating expenses, R&D spend, and SG&A change year‑over‑year, and what impact did they have on the bottom line? How did the market react to the release (price movement, volume) and what does the sentiment index of 70 imply for trader sentiment? What non‑recurring items were excluded from the YoY comparison, and how might similar items impact future quarters? How does ADMA's revenue growth compare to key peers in the biologics/biopharma sector for the same quarter? What were the primary drivers behind the 14% YoY revenue increase and the 29% YoY increase excluding the prior‑year non‑recurring item? What are the major risks highlighted by management (e.g., product development delays, reimbursement challenges, competition) that could affect future performance? What were the adjusted earnings (or loss) per share for the quarter, and how does that compare to analyst consensus estimates?